上海市医药工业研究院和常州制药厂联合试制的巯甲丙脯酸于今年7月上旬在常州市通过鉴定。它是口服有效的血管紧张素转化酶抑制剂,抑制血管紧张素转化成强烈缩血管的血管紧张素Ⅱ;还可抑制血管舒缓素的失活,从而使血压下降。曾经上海市高血压研究所、南京军区总医院及北京、苏州等十几所医院的 Shanghai Pharmaceutical Industry Research Institute and Changzhou Pharmaceutical joint trials of captopril in early July this year, passed in Changzhou City identification. It is an orally available angiotensin-converting enzyme inhibitor that inhibits the conversion of angiotensin into a strongly vasoconstrictive angiotensin II; it also inhibits the inactivation of kallikrein, resulting in a decrease in blood pressure. Once the Shanghai Institute of Hypertension, Nanjing Military Region General Hospital and Beijing, Suzhou and more than a dozen hospitals